Format

Send to

Choose Destination
Infect Drug Resist. 2019 Mar 28;12:709-719. doi: 10.2147/IDR.S196544. eCollection 2019.

Eugenol, a potential schistosomicidal agent with anti-inflammatory and antifibrotic effects against Schistosoma mansoni, induced liver pathology.

Author information

1
Department of Medical Parasitology, Faculty of Medicine, South Valley University, Qena 83523, Egypt, Asmaa.elkady@med.svu.edu.eg.
2
Department of Medical Parasitology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
3
Department of Pathology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
4
Department of Clinical Pathology, Faculty of Veterinary Medicine, South Valley University, Qena 83523, Egypt.
5
Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia.

Abstract

Introduction:

Schistosomiasis is one of the most prevalent parasitic infections in developing countries. Although chemotherapy is one of the main strategies in controlling the disease, it is less effective in reversal of schistosome-induced pathology especially in the chronic and advanced stages of schistosomiasis. New strategies and prospective therapeutic agents with antifibrotic effects are needed. Eugenol has a wide anti-inflammatory effect. In the present study, we investigated the possible antischistosomal effect of eugenol on Schistosoma mansoni.

Materials and methods:

The murine model of S. mansoni was established in three groups of adult male Balb-c mice; group I (infected non-treated group) and groups II and III (infected groups) treated orally with eugenol and praziquantel (PZQ), respectively. The expression of the sensitive immunohistochemical marker α-smooth muscle actin (α-SMA) in schistosome-infected tissues was determined. In addition, parasitological, biochemical, and histological parameters that reflect disease severity and morbidity were examined.

Results:

Eugenol treatment showed significant reduction in total worm burden by 19.2%; however, the oogram pattern showed no marked difference compared to that of the PZQ group. Yet, eugenol significantly reduced the serum levels of hepatic enzymes: aspartate aminotransferase and alanine aminotransferase. Histopathological examination revealed a significant reduction in both numbers and diameters of hepatic granulomata, which was consistent with reduction in collagen fiber deposition. Additionally, the antifibrotic effect of eugenol was validated by its considerable reduction in the expression of the sensitive marker α-SMA in both eugenol- and PZQ-treated groups.

Conclusion:

Although eugenol could not totally eradicate adults of S. mansoni, the significant amelioration of liver enzymes and hepatic fibrosis potentiate eugenol's role as a promising antifibrotic and a complementary antischistosomal agent.

KEYWORDS:

Schistosoma mansoni; anti-inflammatory; eugenol; hepatic stellate cells; liver enzymes; praziquantel

Conflict of interest statement

Disclosure he authors report no conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center